» Articles » PMID: 36566308

MDM4: What Do We Know About the Association Between Its Polymorphisms and Cancer?

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2022 Dec 24
PMID 36566308
Authors
Affiliations
Soon will be listed here.
Abstract

MDM4 is an important p53-negative regulator, consequently, it is involved in cell proliferation, DNA repair, and apoptosis regulation. MDM4 overexpression and amplification are described to lead to cancer formation, metastasis, and poor disease prognosis. Several MDM4 SNPs are in non-coding regions, and some affect the MDM4 regulation by disrupting the micro RNA binding site in 3'UTR (untranslated region). Here, we gathered several association studies with different MDM4 SNPs and populations to understand the relationship between its SNPs and solid tumor risk. Many studies failed to replicate their results regarding different populations, cancer types, and risk genotypes, leading to conflicting conclusions. We suggested that distinct haplotype patterns in different populations might affect the association between MDM4 SNPs and cancer risk. Thus, we propose to investigate some linkage SNPs in specific haplotypes to provide informative MDM4 markers for association studies with cancer.

Citing Articles

SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA.

Yu S, Si Y, Yu J, Jiang C, Cheng F, Xu M Cancer Sci. 2024; 115(12):3915-3927.

PMID: 39329452 PMC: 11611762. DOI: 10.1111/cas.16356.


Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.

Li J, McClellan J, Zhang H, Gao G, Huo D J Natl Cancer Inst. 2024; 116(7):1105-1115.

PMID: 38400758 PMC: 11223833. DOI: 10.1093/jnci/djae041.


Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.

Shen J, Wang Q, Mao Y, Gao W, Duan S MedComm (2020). 2023; 4(3):e288.

PMID: 37256211 PMC: 10225743. DOI: 10.1002/mco2.288.